Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcus Biosciences, Inc. (Arcus) on February 1, 2021, reporting events occurring on January 31, 2021. Arcus is a Delaware corporation with its principal executive offices in Hayward, California, and its common stock trades on the New York Stock Exchange under the symbol "RCUS".
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial event disclosed is a capital transaction:
- Transaction Type: Amended and Restated Common Stock Purchase Agreement with Gilead Sciences, Inc.
- Shares Sold: 5,650,000 shares of Arcus common stock.
- Purchase Price: $39.00 per share.
- Total Proceeds: Approximately $220.35 million (calculated as 5,650,000 shares x $39.00).
- Future Option: Gilead retains an option to purchase additional shares up to a maximum of 35% of Arcus's then-outstanding common stock until July 13, 2025.
Material Changes
The filing discloses the amendment and restatement of the Common Stock Purchase Agreement originally entered into on May 27, 2020. The primary change is the execution of the purchase of the 5,650,000 shares at the specified price. All other terms of the original agreement, including the future purchase option, remain unchanged.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction is subject to customary closing conditions. The sale of shares is conducted pursuant to Section 4(a)(2) of the Securities Act of 1933 as a transaction with an accredited investor.
Investor Verification Checklist
- Verify the closing of the transaction and receipt of proceeds by reviewing subsequent filings or press releases.
- Review the full text of the Amended and Restated Common Stock Purchase Agreement (to be filed as an exhibit to the Form 10-K for the year ended December 31, 2020) for detailed rights and obligations.
- Monitor the impact of the share issuance on total outstanding shares and potential dilution.
- Track the status of Gilead's option to purchase additional shares up to 35% of outstanding stock through July 2025.